TAVR vs Open Heart Surgery for Valve Disease

TAVR and open heart surgery both replace a diseased heart valve, but they go about it in completely different ways. TAVR threads a new valve in through a catheter, no chest incision, and most patients leave hospital within days. Open heart surgery removes the old valve through a sternotomy and offers decades of proven durability. The right choice hinges on surgical risk, age, valve anatomy, and how long the replacement needs to last.

According to Dr. S. A. Merchant, Advanced Heart Failure Specialist in Mumbai, “For an elderly patient with severe aortic stenosis who’d struggle to survive a sternotomy, TAVR is transformative, but for a fit fifty-year-old who needs that valve to last forty years, surgery still has the stronger long-term track record, and pretending otherwise does the patient no favours.”

Both fix the same valve problem. What separates them is invasiveness, recovery, and the kind of patient each suits best.

• The approach is night and day. TAVR slips a folded valve up through the femoral artery and opens it inside the old one, no chest opening at all, whereas surgery means splitting the breastbone and stopping the heart on bypass.
• Recovery tells its own story. Two or three days, that’s the usual hospital stay after TAVR, and most people feel close to normal inside a week. Surgery is a different commitment, often several weeks before someone’s genuinely back on their feet.
• High risk changes the maths. For elderly or frail patients, TAVR has shown lower early mortality time and again. That’s not a marketing claim, it’s the whole reason the procedure was developed in the first place.
• Durability still favours the old guard. Here’s where surgery holds its ground. Surgical valves carry decades of follow-up, and while TAVR valves look strong so far, the long-term numbers in younger patients are only now arriving.

The decision isn’t about which procedure wins in the abstract. It’s about which one fits the person on the table, the same logic that guides choosing a minimally invasive route over open surgery in coronary disease.

This is where it gets personal, because the answer flips completely depending on who’s sitting in front of you.

• Age tilts the scale. Give an eighty-year-old with severe stenosis TAVR and they almost always do better. A low-risk patient in their fifties, though, is a real conversation, since they might outlive the valve and face a re-do down the line.
• Anatomy can overrule preference. Bicuspid valves, dense calcification, narrow or tortuous access through the groin, any of these can push the heart team back toward surgery no matter how fit the patient looks on paper.
• Combined problems change everything. Need a bypass or a second valve dealt with at the same time? Open surgery sorts all of it in a single operation, which TAVR on its own simply can’t.
• The heart team decides, not one doctor. This is the part patients underestimate. A cardiologist, a surgeon, and an imaging specialist reading the scans together is what lands someone on the right answer instead of the easy one.

Get this call right and a patient lives well with that valve for years. Understand why cardiac deaths happen and what are the ways to prevent them.

Dr. S. A. Merchant, DM(Cardiology), MD(MED), DNB(Cardiology), FSCAI(USA), has more than 25 years of interventional cardiology experience, including structural heart work and percutaneous valve therapy alongside complex coronary intervention. He’s a founder member and senior consultant at Lilavati Hospital, and the Cleveland Clinic eHealth Research USA lists him among the world’s leading doctors across 143 countries. Valve decisions here run through a proper heart-team assessment, with detailed imaging and an honest weighing of TAVR against surgery for each patient.

What matters most with valve disease is matching the procedure to the person, not steering everyone toward the same answer. Each patient gets a clear explanation of why one route suits them better than the other.

Call +91-9820930389 to book your consultation.

REFERENCE:

1. Transcatheter versus surgical aortic valve replacement in low-risk patients for severe aortic stenosis. PMC: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7074202/
2. TAVR in low-risk patients: a review of PARTNER 3 and Evolut Low Risk trials. PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC7044101/